Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Nexalin Technology, Inc. ( (NXL) ).
On April 17, 2026, Nexalin Technology entered into a scope of work with UK-based clinical research group Lindus Health to run a pivotal clinical trial of its HALO Clarity device, committing about $944,820 in milestone-based fees plus pass-through costs, with provisions for change orders if the study design expands. The agreement, which runs until all services are completed, underpins full-scope trial execution from protocol finalization through database lock and signals further investment in the company’s U.S. regulatory pathway.
On April 22, 2026, Nexalin announced that its 160-patient, randomized, triple-blinded, sham-controlled insomnia trial is advancing toward expected enrollment in the second quarter of 2026, designed to support a planned De Novo submission to the U.S. FDA that could create a new product category for its DIFS-based neurostimulator. Management highlighted the large, underserved insomnia market and the potential for HALO Clarity, if successful in this study and subsequent regulatory review, to strengthen Nexalin’s position as a differentiated, non-pharmacologic player in the global sleep tech and mental health space and to enhance long-term value for stakeholders.
The most recent analyst rating on (NXL) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Nexalin Technology, Inc. stock, see the NXL Stock Forecast page.
More about Nexalin Technology, Inc.
Nexalin Technology, Inc. is a medical device company that designs and develops non-invasive neurostimulation products aimed at addressing mental health disorders, including insomnia, depression, traumatic brain injury, PTSD, Alzheimer’s disease and ADHD. Its bioelectronic devices, including the next-generation Gen-2 15 milliamp system already approved in China, Brazil, Oman and Israel, are designed to deliver Deep Intracranial Frequency Stimulation believed to reach mid-brain structures linked to these conditions.
The company positions its technology as a drug-free alternative intended to improve patient outcomes without notable adverse side effects, targeting the large and growing global sleep tech and mental health treatment markets. Nexalin’s strategy centers on building a body of peer-reviewed clinical and neuroimaging data to support broader regulatory clearances and commercial adoption of its neurostimulation platform worldwide.
Average Trading Volume: 603,052
Technical Sentiment Signal: Sell
Current Market Cap: $9.6M
For an in-depth examination of NXL stock, go to TipRanks’ Overview page.